Achieve Life Sciences Q3 net loss $13.1M; Phase 3 ORCA-3 and Phase 2 ORCA-V1 enrollment completed

ACHIEVE LIFE SCIENCES, INC.

2022-Q3 EPS reported -$3.24

Net loss of $13.1M for Q3 2022; operating expenses $12.6M; cash and restricted cash $18.2M as of Sept 30, 2022.
Phase 3 ORCA-3 trial of cytisinicline enrolled 750 adult smokers; topline data expected Q2 2023.
Phase 2 ORCA-V1 trial of cytisinicline in 150 e-cigarette users completed enrollment early; topline data expected Q2 2023.
Sopharma completed new API purification suite for cytisinicline with >€3M cost, expanding global production capacity.
9,710,747 shares outstanding as of Nov 10, 2022; no revenue (pre-commercial stage).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACHIEVE LIFE SCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $13.1 million.

Period: the third quarter ended September 30, 2022
Net income: $13.1 million
Result: reported results

Exact text from the filing

Total net loss for the three and nine months ended September 30, 2022 was $13.1 million and $31.1 million, respectively.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ACHIEVE LIFE SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001564590-22-037625

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.